drugset / Trial / NCT05602961
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
RandomizedSequentialQuadruple-blindPrevention
Summary
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against COVID-19, or the 2-dose priming course and a third BNT162b2 injection (i.e., as a "booster"), and, if so, to select the booster dose for further evaluation and potential development.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2024-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT162b2 | Messenger RNA (mRNA) | 30 ug | — |
| Subject | GLB-COV2-043 | Messenger RNA (mRNA) | 15 ug | — |
| Subject | GLB-COV2-043 | Messenger RNA (mRNA) | 30 ug | — |
| Subject | GLB-COV2-043 | Messenger RNA (mRNA) | 60 ug | — |
| Subject | GLB-COV2-043 | Messenger RNA (mRNA) | 90 ug | — |